Document is current

Article History

Received: 14 May 2024

Accepted: 25 July 2024

First Online: 17 August 2024

Declarations

:

: Luis Puig reports consulting fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Samsung-Bioepis, and UCB; payment or honoraria from Janssen, Lilly, Novartis, and UCB; support for attending meetings and/or travel from Janssen and UCB; grants received from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Lilly, Novartis, and UCB; and a non-financial relationship with the International Psoriasis Council. Luis Puig is an Editorial Board member of <i>Dermatology and Therapy</i>. Luis Puig was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Antonio Costanzo reports consulting fees from AbbVie and UCB; payment or honoraria from AbbVie, Almirall, Amgen, Galderma, Janssen, Lilly, Novartis, and UCB; support for attending meetings and/or travel from AbbVie; and participation on a Data Safety Monitoring Board and/or Advisory Board for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Lilly, Novartis, and UCB. Elke de Jong reports receiving research grants from AbbVie, BMS, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, and UCB; and has acted as a consultant, paid speaker, and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis or eczema, including AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Celgene, Galapagos, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, Sanofi, and UCB. Tiago Torres reports consulting fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, and Sanofi; payment or honoraria from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Sandoz, and Sanofi; support for attending meetings and/or travel from AbbVie, Almirall, Janssen, Leo Pharma, MSD, Novartis, Pfizer, and Sanofi; and participation on a Data Safety Monitoring Board and/or Advisory Board for Samsung-Bioepis. Tiago Torres is an Editorial Board member of <i>Dermatology and Therapy</i>. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Richard B. Warren reports consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, GSK, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and UNION; payment or honoraria from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, and UCB; and grants received from AbbVie, Almirall, Janssen, Leo, Lilly, Novartis, Pfizer, and UCB, and is supported by the Manchester NIHR Biomedical Research Facility. Richard B. Warren is an Editor-in-Chief of <i>Dermatology and Therapy</i>. Richard B. Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Robert Wapenaar holds stock at Johnson & Johnson and was a full-time employee of Janssen at the time of the study. Sven Wegner is a full-time employee of and owns stock at Janssen. Patricia Gorecki is a former full-time employee of Janssen and current employee at Kenvue Inc. Talia Gramiccia is a full-time employee at Janssen. Maria Jazra holds stocks at Johnson & Johnson and is a full-time employee at Janssen. Jozefien Buyze is a full-time employee at Janssen. Curdin Conrad reports consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung, Sanofi, and UCB; payment or honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB; participation on a Data Safety Monitoring Board and/or Advisory Board for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, MSD, Novartis, Pfizer, and UCB; grants received from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, and Pfizer; and leadership and/or fiduciary roles for the European Society for Dermatological Research and the Swiss Society for Dermatology and Venereology.

: This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. All participants provided written informed consent. As a post hoc analysis of the VOYAGE 1 clinical trial, ethical approval was not needed.